Clinical trial
AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With…
NCT00076024 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00076024 |
|---|---|
| Title | AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer |
| Official title | Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study Of AG-013736 In Combination With Docetaxel Versus Docetaxel Alone In Patients With Metastatic Breast Cancer Preceded By A Phase 1 Evaluation Of The Combination |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Placebo, Docetaxel, AG-013736 (axitinib) |
| Enrollment | 174 |
| Start date | Feb 1, 2004 |
| Primary completion | Jan 1, 2007 |
| Completion | Nov 1, 2008 |
| First posted | Jan 14, 2004 |
| Last update posted | Jun 26, 2012 |
| Countries | Canada, Czechia, Germany, India, Italy, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: